Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo, AM
Abaurrea, A
Azcoaga, P
López-Velazco, JI
Manzano, S
Rodriguez, J
Rezola, R
Egia-Mendikute, L
Valdés-Mora, F
Flores, JM
Jenkins, L
Pulido, L
Osorio-Querejeta, I
Fernández-Nogueira, P
Ferrari, N
Viera, C
Martín-Martín, N
Tzankov, A
Eppenberger-Castori, S
Alvarez-Lopez, I
Urruticoechea, A
Bragado, P
Coleman, N
Palazón, A
Carracedo, A
Gallego-Ortega, D
Calvo, F
Isacke, CM
Caffarel, MM
Lawrie, CH
- Publisher:
- AMER SOC CLINICAL INVESTIGATION INC
- Publication Type:
- Journal Article
- Citation:
- J Clin Invest, 2022, 132, (7), pp. e148667
- Issue Date:
- 2022-04-01
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Araujo, AM | |
dc.contributor.author | Abaurrea, A | |
dc.contributor.author | Azcoaga, P | |
dc.contributor.author | López-Velazco, JI | |
dc.contributor.author | Manzano, S | |
dc.contributor.author | Rodriguez, J | |
dc.contributor.author | Rezola, R | |
dc.contributor.author | Egia-Mendikute, L | |
dc.contributor.author | Valdés-Mora, F | |
dc.contributor.author | Flores, JM | |
dc.contributor.author | Jenkins, L | |
dc.contributor.author | Pulido, L | |
dc.contributor.author | Osorio-Querejeta, I | |
dc.contributor.author | Fernández-Nogueira, P | |
dc.contributor.author | Ferrari, N | |
dc.contributor.author | Viera, C | |
dc.contributor.author | Martín-Martín, N | |
dc.contributor.author | Tzankov, A | |
dc.contributor.author | Eppenberger-Castori, S | |
dc.contributor.author | Alvarez-Lopez, I | |
dc.contributor.author | Urruticoechea, A | |
dc.contributor.author | Bragado, P | |
dc.contributor.author | Coleman, N | |
dc.contributor.author | Palazón, A | |
dc.contributor.author | Carracedo, A | |
dc.contributor.author | Gallego-Ortega, D | |
dc.contributor.author | Calvo, F | |
dc.contributor.author | Isacke, CM | |
dc.contributor.author | Caffarel, MM | |
dc.contributor.author | Lawrie, CH | |
dc.date.accessioned | 2023-02-27T19:14:32Z | |
dc.date.available | 2022-02-16 | |
dc.date.available | 2023-02-27T19:14:32Z | |
dc.date.issued | 2022-04-01 | |
dc.identifier.citation | J Clin Invest, 2022, 132, (7), pp. e148667 | |
dc.identifier.issn | 0021-9738 | |
dc.identifier.issn | 1558-8238 | |
dc.identifier.uri | http://hdl.handle.net/10453/166466 | |
dc.description.abstract | The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression. | |
dc.format | ||
dc.language | eng | |
dc.publisher | AMER SOC CLINICAL INVESTIGATION INC | |
dc.relation.ispartof | J Clin Invest | |
dc.relation.isbasedon | 10.1172/JCI148667 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 11 Medical and Health Sciences | |
dc.subject.classification | Immunology | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fibroblasts | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Oncostatin M | |
dc.subject.mesh | Signal Transduction | |
dc.subject.mesh | Tumor Microenvironment | |
dc.subject.mesh | Fibroblasts | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Signal Transduction | |
dc.subject.mesh | Female | |
dc.subject.mesh | Oncostatin M | |
dc.subject.mesh | Tumor Microenvironment | |
dc.title | Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. | |
dc.type | Journal Article | |
utslib.citation.volume | 132 | |
utslib.location.activity | United States | |
utslib.for | 11 Medical and Health Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2023-02-27T19:11:55Z | |
pubs.issue | 7 | |
pubs.publication-status | Published | |
pubs.volume | 132 | |
utslib.citation.issue | 7 |
Abstract:
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph